Yulin Red Cross Hospital

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)1 trial
• Immune thrombocytopenia (ITP)1 trial
• Thalassaemia1 trial
• Type 1 diabetes1 trial

Phase

• Phase 23 trials

Status

• Not yet recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1 trial
• Hangzhou Sumgen Biotech Co., Ltd.1 trial
• Nanjing First Hospital, Nanjing Medical University1 trial
• Rongrong Liu1 trial

Running trials

• Recruiting

  SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

  NCT07710248· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source

  Contact: Zhao Lv

• Not yet recruiting

  The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

  NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source

  Contact: Bingna Yao, Doctor

• Recruiting

  Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

  NCT06657391· Phase 2· Rongrong Liu· Source

  Contact: Hua Zhang

• Recruiting

  Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

  NCT06569524· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

  Contact: Yu Wang, Master

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Thalassaemia1 recruiting
• Type 1 diabetes1 recruiting